EyePoint Pharmaceuticals, Inc. Stock News

EyePoint stock is heading for its largest single-day percentage drop on record.

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for DURAVYU™ in diabetic macular edema (DME).

– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpoints in LUCIA were met including a superior 38% reduction in treatment burden (nominal p-value

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company's 2023 Long-Term Incentive Plan in accordance with N...

LOS ANGELES--(BUSINESS WIRE)---- $EYPT--EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law.

Duravyu, EyePoint's candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

EyePoint stock crashed Monday after its eye disease treatment, Duravyu, missed the mark in a final-phase study.